BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc. (www.saladax.com), developer of the Personalized Chemotherapy Management (PCM®) line of tests to measure blood levels of cancer drugs, has signed an agreement with the Karolinska University Hospital, of Stockholm, Sweden.
